{
    "clinical_study": {
        "@rank": "43456", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The objective of this PMS is to gain information about safety and efficacy in real practice\n      as a regulatory commitment required by KFDA."
        }, 
        "brief_title": "Eylea Regulatory Post Marketing Surveillance(rPMS)", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients determined to start EYLEA treatment\n\n          -  Patients who are prescribed with anti-VEGF therapy for the first time\n\n        Exclusion Criteria:\n\n          -  Patients who previously received anti-VEGF therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with wet age-related macular degeneration(wAMD) who are decided to\n        receive EYLEA (VEGF Trap Eye) treatment"
            }
        }, 
        "enrollment": {
            "#text": "3600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783925", 
            "org_study_id": "16469", 
            "secondary_id": "EY1310KR"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.", 
            "intervention_name": "Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Eylea Regulatory Post Marketing Surveillance in Korea", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783925"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart.[BCVA: Best Corrected Visual Acuity]", 
                "safety_issue": "No", 
                "time_frame": "4 months or 8 months"
            }, 
            {
                "measure": "Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography]", 
                "safety_issue": "No", 
                "time_frame": "4 months or 8 months"
            }, 
            {
                "measure": "Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography", 
                "safety_issue": "No", 
                "time_frame": "4 months or 8 months"
            }, 
            {
                "measure": "IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure]", 
                "safety_issue": "No", 
                "time_frame": "4 months or 8 months"
            }, 
            {
                "measure": "Measurement of fundus lesion by fundoscopy", 
                "safety_issue": "No", 
                "time_frame": "4 months or 8 months"
            }, 
            {
                "measure": "Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "8 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}